Profile data is unavailable for this security.
About the company
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
- Revenue in USD (TTM)832.01k
- Net income in USD-135.12m
- Incorporated2001
- Employees122.00
- LocationInovio Pharmaceuticals Inc6769 Mesa Ridge Rd.SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 410-3134
- Fax+1 (858) 404-1392
- Websitehttps://www.inovio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 273.55m | 145.00 | -- | 1.65 | -- | 3.75 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
XOMA Corp | 4.76m | -46.30m | 275.63m | 13.00 | -- | 3.07 | -- | 57.93 | -4.04 | -4.04 | 0.4148 | 7.72 | -- | -- | -- | 366,000.00 | -- | -4.55 | -- | -4.94 | -- | -- | -858.15 | -31.87 | -- | -- | 0.583 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
ESSA Pharma Inc | 0.00 | -25.80m | 276.49m | 50.00 | -- | 1.96 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 278.72m | 377.00 | -- | -- | -- | 1.70 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Akebia Therapeutics Inc | 194.62m | -51.93m | 278.76m | 167.00 | -- | -- | -- | 1.43 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Medifast Inc | 897.81m | 67.76m | 281.31m | 634.00 | 4.15 | 1.33 | 3.47 | 0.3133 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 283.18m | 122.00 | -- | 2.17 | -- | 340.36 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Sanara Medtech Inc | 64.99m | -4.30m | 285.59m | 107.00 | -- | 6.31 | -- | 4.39 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
Fibrobiologics Inc | 0.00 | -19.06m | 285.97m | 10.00 | -- | 227.63 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -77.11m | 287.24m | 59.00 | -- | 2.42 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Invivyd Inc | 0.00 | -198.64m | 288.52m | 94.00 | -- | 1.50 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 291.34m | 449.00 | -- | 6.55 | -- | 4.83 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 291.57m | 203.00 | 114.25 | 0.529 | 52.83 | 1.51 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
Candel Therapeutics Inc | 0.00 | -37.94m | 292.59m | 42.00 | -- | 22.76 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Zura Bio Ltd | 0.00 | -69.24m | 292.95m | 14.00 | -- | 3.38 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Nektar Therapeutics | 90.17m | -175.84m | 293.80m | 137.00 | -- | 2.32 | -- | 3.26 | -0.9195 | -0.9195 | 0.4709 | 0.6901 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | -- | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.64m | 7.02% |
Renaissance Technologies LLCas of 31 Dec 2023 | 608.11k | 2.60% |
Deep Track Capital LPas of 26 Apr 2024 | 458.35k | 1.96% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 327.71k | 1.40% |
Geode Capital Management LLCas of 31 Dec 2023 | 239.29k | 1.02% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 225.10k | 0.96% |
Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 95.83k | 0.41% |
GSA Capital Partners LLPas of 31 Mar 2024 | 79.98k | 0.34% |
Acadian Asset Management LLCas of 31 Dec 2023 | 74.08k | 0.32% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 72.59k | 0.31% |